---
title: "Faeth Therapeutics Partners With Roche on Phase 1b/2 Trial of PIKTOR Combination in Advanced Breast Cancer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305666750.md"
description: "Faeth Therapeutics has partnered with Roche for a Phase 1b/2 trial of PIKTOR combined with giredestrant in advanced hormone receptor-positive, HER2-negative breast cancer. Faeth will sponsor and conduct the study while retaining rights to PIKTOR, an all-oral combination targeting endocrine therapy resistance. Roche will supply giredestrant."
datetime: "2026-11-16T12:03:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305666750.md)
  - [en](https://longbridge.com/en/news/305666750.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305666750.md)
generator: "portal-rs"
---

# Faeth Therapeutics Partners With Roche on Phase 1b/2 Trial of PIKTOR Combination in Advanced Breast Cancer

-   Faeth Therapeutics entered a clinical trial collaboration with Roche to evaluate PIKTOR in combination with investigational breast cancer drug giredestrant. \* The planned Phase 1b/2 study will evaluate the combination in patients with hormone receptor-positive, HER2-negative advanced breast cancer. \* PIKTOR is an investigational all-oral combination of serabelisib and sapanisertib targeting a pathway associated with resistance to endocrine therapy. \* Faeth will sponsor and conduct the trial while retaining all PIKTOR rights. Roche will supply giredestrant. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faeth Therapeutics Inc published the original content used to generate this news brief via Business Wire (Ref. ID: 202611160700BIZWIRE\_USPR\_\_\_\_\_20261116\_BW192980) on November 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [FTH.US](https://longbridge.com/en/quote/FTH.US.md)
- [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md)

## Related News & Research

- [Roche Wins Dual FDA Approvals for Breast Cancer and Chronic Kidney Disease Therapies](https://longbridge.com/en/news/305863519.md)
- [FDA approves Roche’s Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer | RHHBY Stock News](https://longbridge.com/en/news/305729180.md)
- [Roche Holding (SWX:ROP) Wins FDA Clears In Breast Cancer And Kidney Disease](https://longbridge.com/en/news/306181148.md)
- [Faeth Therapeutics (FTH): Betting On Multi-Node Blockade To Disrupt Cancer Growth](https://longbridge.com/en/news/305655504.md)
- [Genentech’s Gazyva Becomes the First FDA-Approved Treatment for Primary Membranous Nephropathy | RHHBY Stock News](https://longbridge.com/en/news/305621107.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**